Illumina Diagnostics. Emily Winn-Deen, PhD Vice President, Product Development Diagnostics

Transcription

1 Introduction ti to Illumina Diagnostics Emily Winn-Deen, PhD Vice President, Product Development Diagnostics 2010 Illumina, Inc. All rights reserved. Illumina, illuminadx, Solexa, Making Sense Out of Life, Oligator, Sentrix, GoldenGate, GoldenGate Indexing, DASL, BeadArray, Array of Arrays, Infinium, BeadXpress, VeraCode, IntelliHyb, iselect, CSPro, GenomeStudio, Genetic Energy, and HiSeq are registered trademarks or trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners.

2 Corporate Overview Founded in 1998 Initial Public Offering on July 27, 2000 Headquarters in San Diego, CA More than 500,000 square ft. of facility space in 6 countries Over 1,800 employees IP portfolio of 135 issued patents and 168 pending applications Ranked #1 on Forbes list of Fastest Growing Technology Companies in 2009 & 2007 Added to the NASDAQ-100 listing in

3 A Global Organization Expanded Manufacturing, R&D, Sales, Service & Support Illumina BV (The Netherlands) Illumina China (Beijing) Illumina Hayward (Hayward, CA) Illumina Global Headquarters (San Diego, CA) Illumina Cambridge Jinan, China Chengdu, China India Thailand Kore a Illumina KK (Tokyo) Shanghai Taiwan Vietnam Illumina Singapore Malaysia Commercial Mfg/R&D Partners Over 1800 Employees >150 Sales Personnel >300 Customer Solutions Personnel Australia New Zealand 4

4 Markets Served Molecular Dx ~$3B Life Sciences ~$2.8B Applied Markets ~$1B Consumer 5

5 Growth Opportunities for Genetic Analysis Total Addressable Market Today: ~$6.6B Pharma & Applied Markets High to Low Complexity Arrays Sequencing Market estimates in $billions 6

6 Industry Leading Growth Strong Performance While Reinvesting in New Opportunities 53% Revenue CAGR $700 $600 $500 $400 $300 $200 Revenue Operating Profit EPS $0.56 $0.93 $1.00 $0.90 $0.80 $0.62 $0.70 $0.60 $573 $0.50 $662 $0.40 $367 $0.30 $100 $0 $185 $169 $52 $ Estimate Non-GAAP Operating Profit and Earnings per Share $0.20 $0.10 $0.00 7

7 Integrated Solutions That Advance the Understanding of Genetics and Health HiSeq 2000 iscan BeadXpress Whole Genome, Regulatory & Targeted Sequencing Whole Genome, Targeted & Custom Microarrays Low Complexity Targeted, Custom Arrays 8

8 Supporting Rich & Divergent Applications VARIANT ANALYSIS METHYLATION ANALYSIS ChIP SEQUENCING de novo SEQUENCING COMPLETE RNA PROFILING 9

9 Resources to Provide Complete Solutions icontroldb Automation COMPLETE SYSTEMS Systems Software Assays & Reagents 10

10 Illumina s Matrixed Organization Functions Business Units Life Sciences Diagnostic Business Business Commercial Operations Materials & Business Apps Research/Services & New Technologies Market Dev & Collaborations Legal & Administration Finance & Investor Relations 11

11 IlluminaDx Vision Our vision is to become a leader in translational medicine, focusing on complex diseases that benefit from high performance analysis, including genotyping, copy number, gene expression, methylation and protein analysis. We leverage the strength of our technologies in four major areas: Molecular Molecular Clinical Oncology Diagnostics Cytogenetics Services Discovery 12

12 The Next Generation of Molecular Diagnostic Tests, Systems, and Services Seminar Schedule 900 9:00 Registration i 9:30 Introduction to IlluminaDx Emily Winn-Dean, VP of Product Development of Diagnostics, Illumina 9:45 Maximizing the Multiplexing Capabilities of the BeadXpress System Gianluca Roma, Illumina 10:00 Pharmacogenetics Research Standardized : The ADME Core List and VeraCode ADME Core Panel 10:30 Identifying Chromosomal Abnormalities Using Infinium SNP BeadChips Michael Phillips, PhD Montreal Heart Institute Pharmacogenomics Centre Harper VanSteenhouse, PhD, Illumina and Michael Phillips, PhD Montreal Heart Institute Pharmacogenomics Centre 11:15 Clinical Genome Sequencing Service Julianne O Daniel, CGC, Illumina 12:00 Lunch Café 1:00 A Platform Approach to Translational Cancer Discovery and Diagnostic Development 1:45 Conclusion Naomi O Grady, Illumina 13